SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

BIOCON

BSE: 532523 30 Sep 2025
Healthcare
₹ 358.45
Biocon Ltd. specializes in Pharmaceuticals within the Healthcare sector.

BIOCON - Share Price & Details

Market Cap
₹45,310
High /Low
406.0 / 291.0
Stock P/E
125.0
Book Value
₹180.0
Dividend Yield
0.15
ROCE
6.25
ROE
₹4.76
Face Value
5.0
PEG Ratio
11.9
EVEBITDA
₹17.3
Debt
18,362
CMP / FCF
47.0
Debt to equity
₹0.85
NP Ann
1,429
High price all time
488.0
Piotroski score
₹6.0
Graham Number
114.0
No. Eq. Shares
134.0
Net CF
₹2,004
Net profit
657
Price to book value
1.88
Interest Coverage
₹1.82
Low price all time
14.2
Industry PE
33.0
Reserves
₹21,044
Free Cash Flow
₹1,718

Broker Recommendations

Date Author Type Reco Price Target Price Potential Source PDF Link
09 Aug 2025 ICICI Securities Sell ₹343.35 ₹270 -24.8% moneycontrol View
08 Aug 2025 Motilal Oswal Buy ₹343.35 ₹410 19.8% moneycontrol View
13 Jan 2025 Motilal Oswal Buy ₹364.8 ₹430 17.7% moneycontrol View
20 Nov 2024 Geojit Financial Services Buy ₹327.1 ₹376 0% moneycontrol View
12 Nov 2024 Sharekhan Buy ₹347.65 ₹400 6.3% moneycontrol View
04 Jul 2024 Sharekhan Buy ₹361.1 ₹400 6.9% moneycontrol View
17 Jan 2024 Sharekhan Buy ₹279.8 ₹332 -11.1% moneycontrol View

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
FABINO ENTERPRISES LIMITEDNANANANA5.0984.8
Triochem Products Ltd.,NANANANA0
BIOCON LTD.5984.0-83.05371.0-0.0745,310125.0
GLAXOSMITHKLINE PHARMACEUTICAL8485.92047.08048.312.084527247.8
Laurus Labs Limited14542.71579.414327.52.934493088.3

Peer Comparison Chart


About BIOCON

Biocon Ltd., with Security Code 532523, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.


Order Book


Latest News

Bridging Continents, Saving Lives: Biocon First Manufacturing Facility in The U.S.

(22 Sep 2025)
In a proud moment for Indian innovation as well as Healthcare worldwide, Biocon Limited has officially inaugurated its first manufacturing...
Read more →

Biocon Biologics’ retinal disorder medication Yesafili gets public funding in Canada

(22 Sep 2025)
Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada.
Read more →

Biocon Limited's (NSE:BIOCON) Intrinsic Value Is Potentially 56% Above Its Share Price

(22 Sep 2025)
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Biocon Limited (NSE:BIOCON) as an...
Read more →

Biocon unit gets public funding for retinal disorder medication

(19 Sep 2025)
Biocon Ltd announced that its subsidiary Biocon Biologics Ltd (BBL), announced that Yesafili (aflibercept) is now publicly funded in Ontario...
Read more →

Biocon arm's retinal disorder medication Yesafili gets public funding in Canada

(19 Sep 2025)
Biocon Ltd's subsidiary, Biocon Biologics Ltd (BBL), announced that Yesafili (aflibercept), its biosimilar to Eylea, is now publicly funded...
Read more →

Biocon arm gets Ontario listing for retinal drug; check details

(19 Sep 2025)
Shares of Biocon settled at 4.25% higher at ₹369.40 apiece on the National Stock Exchange (NSE) on Thursday. The stock touched its 52 week...
Read more →